ResMed now finds itself forced to justify both its product pipeline and its capital allocation decisions.
The main non-core asset in focus is MatrixPartners, a US business ResMed acquired in 2018 for US$750 million. MatrixPartners serves aged care sectors and related facilities rather than ResMed’s traditional sleep apnoea patient base.
The unit is forecast to generate around US$200 million in annual revenue and about US$55 million in earnings in the 2025-26 financial year. Those numbers matter because investors are weighing whether this side business still earns its place on the balance sheet.
Analysts point out that MatrixPartners, while profitable, ties up capital that could be redeployed into ResMed’s core sleep health and respiratory care franchise. The aged care-focused business operates adjacent to the company’s main competitive battleground where devices, masks and digital solutions drive long-term growth.
Some market watchers argue that monetising MatrixPartners could help ResMed sharpen its focus just as Philips Respironics prepares to step back into the US sleep apnoea market. Others counter that the earnings contribution, though modest, provides diversification at a time of product-related scrutiny.
Strategic clarity has become the bigger debate. ResMed is being pushed to spell out whether assets such as MatrixPartners remain part of the long-term plan or potential candidates for divestment.
Philips Respironics’ re-entry into the US market is expected to raise competitive intensity and tighten pricing across sleep apnoea devices. Against that backdrop, investors are most interested in how quickly ResMed can streamline around its highest-return franchises while managing legacy product issues without further distraction.
